Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...
ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...
Array BioPharma and Bristol-Myers Squibb Co. are investigating the safety, tolerability and efficacy of Array’s investigational MEK inhibitor binimetinib when used with Bristol Myers Squibb’s Opdivo ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
* Array to receive $12 million in up-front payment and up to $64 million in additional development and commercialization milestones * Array retains full commercialization rights for all compounds in ...
* Array Biopharma Inc - FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - FDA set a target action ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback